The Power Of Efficient Multi-Center Studies

Registries seek to inspire collaboration among dispersed practitioners.  They offer the promise of aggregating many smaller but similar studies into large databases, from which statistically significant correlations can be derived.  In practice, however, this promise remains largely unmet.  The American Medical Association has famously described many such “big data” claims as “digital snake oil”.

Registry Challenges

This is not surprising, since registries generally suffer from one or more of the following deficiencies:

  • Data are submitted sporadically, partially and often without clear clinical context.
  • Practitioners spend precious time after their clinical activities in submitting data, without compensation or other benefit.
  • Practitioners submitting data to registries often forego ownership rights to such data.
  • It is difficult or impossible to verify the accuracy or quality of the data.
  • Access to and the ability to query registry datasets are limited.
  • Registry data are submitted in inconsistent, unspecified and/or clinically unhelpful formats.

RegenMed Registry Solution

RegenMed’s platforms and processes address these deficiencies:

  • Practitioners can easily collaborate with peers of their choosing within or across institutional and national boundaries on any desired set of endpoints, indications, clinical intervention, or other study parameter.
  • Practitioners control ownership and use of, and access to, their data.
  • Registry datasets are available 24/7/365 from any device to generate a wide variety of practitioner-defined correlations.
  • All registry data are standardized, verifiable, HIPAA/GDPR compliant, and fully downloadable.
  • Registry data comprise real-world data.  They thus represent immediate benefits to practitioners in terms of reimbursement, clinical decision-making, publication, patient education, legal/regulatory compliance and other objectives.
  • Providers can introduce practice-specific variations to the underlying registry protocols, while preserving the integrity of larger integrated datasets.
  • Industry can fund any number of related investigator-initiated studies, while eliminating control and legal liability issues.
Get startedContact Us

Related Articles